The estimated Net Worth of Thomas R Cannell is at least $2.04 million dollars as of 2 March 2023. Mr. Cannell owns over 606,800 units of Sesen Bio stock worth over $599,099 and over the last 8 years he sold SESN stock worth over $31,699. In addition, he makes $1,404,240 as President, Chief Executive Officer et Director at Sesen Bio.
Sign up
Mr. Cannell SESN stock SEC Form 4 insiders trading
Thomas has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 606,800 units of SESN stock worth $358,012 on 2 March 2023.
The largest trade he's ever made was exercising 606,800 units of Sesen Bio stock on 2 March 2023 worth over $358,012. On average, Thomas trades about 50,810 units every 1 days since 2016. As of 2 March 2023 he still owns at least 950,950 units of Sesen Bio stock.
You can see the complete history of Mr. Cannell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Cannell biography
Thomas R. Cannell serves as President, Chief Executive Officer, Director of the Company. rior to joining us, Dr. Cannell served as Orexigen Therapeutics, Inc.’s Chief Operating Officer & President of Global Commercial Products from July 2016 to July 2018, and as its Chief Commercial Officer from March 2015 to June 2016. While at Orexigen, Dr. Cannell led the successful commercialization and profitability of Contrave®. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as President and Managing Director of Merck Canada from December 2012 to October 2014, and Chief Marketing Officer & Chief Strategy Officer for MSD Japan, a subsidiary of Merck & Co., from 2010 to 2012 where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.
What is the salary of Thomas Cannell?
As the President, Chief Executive Officer et Director of Sesen Bio, the total compensation of Thomas Cannell at Sesen Bio is $1,404,240. There are no executives at Sesen Bio getting paid more.
How old is Thomas Cannell?
Thomas Cannell is 58, he's been the President, Chief Executive Officer et Director of Sesen Bio since 2018. There are 7 older and 9 younger executives at Sesen Bio. The oldest executive at Sesen Bio Inc. is Dr. Glen C. MacDonald, 70, who is the Chief Technology Officer.
What's Thomas Cannell's mailing address?
Thomas's mailing address filed with the SEC is C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Insiders trading at Sesen Bio
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes et Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
What does Sesen Bio do?
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
What does Sesen Bio's logo look like?
Complete history of Mr. Cannell stock trades at Sesen Bio
Sesen Bio executives and stock owners
Sesen Bio executives and other stock owners filed with the SEC include:
-
Thomas Cannell,
President, Chief Executive Officer, Director -
Mark Sullivan,
General Counsel, Corporate Secretary -
Dr. Thomas R. Cannell,
Pres, CEO & Director -
Monica Forbes,
Chief Financial Officer, Treasurer -
Monica Forbes,
CFO & Treasurer -
Dr. Glen C. MacDonald,
Chief Technology Officer -
Jason Keyes,
Independent Director -
Carrie Bourdow,
Independent Director -
Jane Henderson,
Independent Director -
Jay Duker,
Independent Chairman of the Board -
Glen MacDonald,
Chief Technology Officer -
Daniel Lynch,
Independent Director -
John Knighton,
VP & Chief Compliance Officer -
Dr. Gregory L. Verdine Ph.D.,
Co-Founder -
Dr. David Brooks,
Sr. VP of Clinical Devel. -
Julie Hoff,
VP of HR -
Steve Barbera,
VP of Market Access -
Mark R. Sullivan,
Gen. Counsel & Corp. Sec. -
Erin Clark,
VP of Corp. Strategy & Investor Relations -
Elly Ryu,
Corp. Controller & Principal Accounting Officer -
Dr. Gregory L. Verdine,
Co-Founder -
Minori Rosales,
Chief Development Officer -
Leslie Dan,
Director -
Paul G Chaney,
Director -
Abbie Celniker,
Director -
Stephen A Hurly,
President and CEO -
Wendy L Dixon,
Director -
Dennis Kim,
Chief Medical Officer -
Richard F Fitzgerald,
Chief Financial Officer -
Peter Honig,
Director -
Michael A. S. Jewett,
Director -
Kirstin Anderson,
Principal Accounting Officer -
Elly Ryu,
Principal Accounting Officer